ABBVIE INC. vs. Apimeds Pharmaceuticals US, Inc.
ABBVIE INC. and Apimeds Pharmaceuticals US, Inc. are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| ABBV | APUS | |
|---|---|---|
| Market Cap | $467.12 billion | $7.42 million |
| Revenue (TTM) | $64.39 billion | — |
| Net Income (TTM) | $6.32 billion | — |
ABBV leads on 1 of 1 size & scale factors.
Valuation
| ABBV | APUS | |
|---|---|---|
| P/E Ratio | 74.67 | — |
| Price / Book | -79.33 | — |
| Price / Sales | 7.25 | — |
ABBV and APUS split the valuation factors evenly.
Profitability
| ABBV | APUS | |
|---|---|---|
| Net Margin | 9.81% | — |
| Return on Equity | -107.29% | — |
ABBV and APUS split the profitability factors evenly.
Dividend
| ABBV | APUS | |
|---|---|---|
| Dividend Yield | 2.62% | — |
| Payout Ratio | 195.48 | — |
ABBV and APUS split the dividend factors evenly.
Risk & Sentiment
| ABBV | APUS | |
|---|---|---|
| Short Interest | 0.85% | 0.69% |
APUS leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABBV overview, ABBV financials, APUS overview, APUS financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.